Drilling Down Into Exelixis, Inc. (EXEL)

Exelixis, Inc. (EXEL) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $28.80, down from yesterday’s close by -0.86%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Exelixis, Inc. (EXEL) currently trades with a market capitalization of $8.34 Billion. That value represents a market adjusting for revenues that have been growing by 145.22 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $191.94 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.12 on a per share basis this quarter. Perhaps, that suggests something about why 1.64% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Exelixis, Inc. recorded a 52-week high of $32.50. It is now trading 3.7% off that level. The stock is trading $28.99 its 50-day moving average by 0.19%. The stock carved out a 52-week low down at $18.03.

In recent action, Exelixis, Inc. (EXEL) has made a move of -2.87% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 13.62, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 5.65% with $285.66 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EXEL.

Previous articleTake-Two Interactive Software, Inc. (TTWO): From Top to Bottom
Next articleThe Case for and Against LKQ Corporation (LKQ)